Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Netherlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Netherlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Media
Contact
Show Search
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Innovative Medicine
/
Newsroom
Newsroom
The latest news from Johnson & Johnson Innovative Medicine.
Press releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
998 Results
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
998 results
Filters
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
Innovative Medicine
May 20, 2025
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma
Read more
Innovative Medicine
May 20, 2025
Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools
Read more
Innovative Medicine
May 15, 2025
Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025
23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio
Read more
Innovative Medicine
May 9, 2025
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill
Read more
Innovative Medicine
May 5, 2025
Johnson & Johnson’s New “Oncology Care Index” Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice
73% of surveyed HCPs say there’s a gap between the availability of new, cutting-edge treatments and their successful implementation in clinical practice; 3 in 4 oncologists find the pace of new treatment development overwhelming Insights will boost Johnson & Johnson’s strong approach to supporting oncologists with the resources and opportunities needed to enhance patient care and stay informed on emerging treatments.
Read more
Innovative Medicine
May 5, 2025
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn’s disease
Read more
Load More